| Expression pattern: |
DN |
| Associated gene: |
SLC7A11, TRIM21, GPX4 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits prostate cancer cell proliferation, promotes apoptosis, suppresses tumor growth, and induces ferroptosis. |
| Molecular mechanism: |
Protein-coding circular chimeric RNA; encodes CCDC7241aa that interacts with SLC7A11 and enhances TRIM21-mediated K48-linked ubiquitination and proteasomal degradation of SLC7A11, triggering ferroptosis. |
| Biological pathway or process: |
ferroptosis (promotes); proliferation (inhibits); apoptosis (promotes); ubiquitination (promotes) |
| Detected method: |
Q
H
S
|
| Validation methods: |
RNA-seq; RT-qPCR; FISH / smFISH; Clinical Sample Validation; Survival Analysis; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; Actinomycin D / DRB Stability Assay; Transfection; MTT; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Flow Cytometry（Non-apoptosis/cycle）; Western Blot; Co-IP; RNA Pull-Down; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining; ELISA; Bioinformatics Analysis |
| Clinical significance: |
Low CCDC719-13 levels serve as an independent predictor of poor prognosis; high CCDC719-13 expression is associated with improved progression-free survival and overall survival. |
| Description: |
CCDC719-13 is down-regulated in advanced/recurrent prostate cancer and serves as an independent prognostic marker. Its tumor-suppressive activity is mainly mediated by its encoded protein CCDC7241aa, which promotes TRIM21-dependent ubiquitination and degradation of SLC7A11, inducing ferroptosis and reducing tumor growth; recombinant CCDC7241aa also enhances docetaxel/enzalutamide efficacy in vitro. |
| Confidence score: |
0.8793 |